References

Publication Details

  1. Adamson JW, Schuster M, Allen S, et al Effectiveness of recombinant human erythropoietin therapy in myelodysplastic syndromes Acta Haematol 199287(Suppl 1):20–4. [PubMed: 1574963]
  2. Adamson JW, Vapnek D Recombinant erythropoietin to improve athletic performance. N Engl Med. 1991;324:698–9. [PubMed: 1994258]
  3. Albitar S, Meulders Q, Hammoud H, et al Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant. 1995;10:40–3. [PubMed: 8524493]
  4. Quality of life resource:The Nottingham Health Profile (NHP).Available at:http://www.atsqol.org/nott.html. Accessed April 2000.
  5. Epogen® (epoetin alfa) prescribing information.In:Physicians' desk reference. 53rd ed. Montvale: Medical Economics Press; 1999.
  6. Benz RL, Pressman MR, Hovick ET, et al A preliminary study of theeffects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO Study) Am J Kidney Dis 199934(6):1089–95. [PubMed: 10585319]
  7. Besarab A, Bolton WK, Browne JK, et al The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 1998 Aug 27339(9):584–90. [PubMed: 9718377]
  8. Besarab A, Flaherty KK, Erslev AJ, et al Clinical pharmacology and economics of recombinant erythropoietin end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol. 1992;2(9):1405–16. [PubMed: 1627763]
  9. Brandt JR, Avner ED, Hickman RO, et al Safety and efficacy of erythropoietin in children with chronic renal failure Pediatric Nephrol 199913(2):143–7. [PubMed: 10229004]
  10. Brenner BM, Lazarus JM Chronic renal failure. In:Harrisons:Principles and practice of internal medicine.13th ed., Vol. 2.New York: McGraw-Hill Inc. Health Professions Division; 1994. p. 1274-81.
  11. Bunn HF Pathophysiology of the anemias. In: Harrisons: Principles and practice of internal medicine. 13th ed., Vol. 2. New York: McGraw-Hill Inc. Health Professions Division; 1994a. p. 1717-21.
  12. Bunn HF Anemia associated with chronic disorders. In: Harrisons: Principles and practice of internal medicine. 13th ed., Vol. 2. New York: McGraw-Hill Inc. Health Professions Division; 1994b. p. 1732-4.
  13. Canaud B, Bennhold I, Delons S, et al What is the optimum frequency of administration of r-huepo for correcting anemia in hemodialysispatients? Dial Transplant. 1995;24:306–9.
  14. Carson JL, Duff A, Poses RM, et al Effect of anaemia and cardiovascular disease on surgical mortality and morbidity Lancet 1996348(9034):1055–60. [PubMed: 8874456]
  15. Catlin DH, Hatton CK Use and abuse of anabolic and other drugs. Adv Intern Med. 1991;36:399–424. [PubMed: 1673818]
  16. Collins A, Hao W, Ebben J, et al Anemia correction in incident peritoneal dialysis patients is associated with lower hospitalization risk. J Am Soc Nephrol. 1999a;10:–.
  17. Collins A, Hao W, Ebben J, et al Higher hematocrit levels in incident hemodialysis patients are associated with lower hospitalization risks. J Am Soc Nephrol. 1999b;10:157A–158A. [PubMed: 10361870]
  18. Collins A, Hao W, Ebben J, et al Hematocrit associated outcomes in incident peritoneal and hemodialysis patients. Abstracts, XVth International Congress of Nephrology, Buenos Aires, Argentina. May 2-6, 1999c.p. 70 (Abstract #280).
  19. Collins AJ, Ma JZ, Xia A, et al Trends in anemia treatment with erythropoietin usage and patient outcomes Am J Kidney Dis 1998 Dec32(6 Suppl 4):S133–S141. [PubMed: 9892380]
  20. Eschbach JW, Glenny R, Robertson T, et al Normalizing the hematocrit (HCT) in hemodialysis patients (HDP) with EPO improves quality of life (Q/L) and is safe. J Am Soc Nephrol. 1993;4:–.
  21. Faulds D, Sorkin EM Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 1989 Dec;38(6):863-99. [PubMed: 2693045]
  22. Foley RN, Parfrey PS, Morgan J, et al A randomized controlled trial of complete vs. partial correction of anemia in hemodialysis patients withasymptomatic concentric LV hypertrophy or LV dilatation. J Am Soc Nephrol. 1998;9:–.
  23. Frankenfield DL, Prowant BF, Flanigan MJ, et al Trends in clinical indicators of care for adult peritoneal dialysis patients in the United States from 1995 to 1997. Kidney Int. 1999;55:1998–2010. [PubMed: 10231465]
  24. Halstenson CE, Macres M, Katz SA, et al Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta Clin Pharmacol Ther 1991 Dec50(6):702–12. [PubMed: 1752115]
  25. Henry DH Epoetin alfa and high-dose chemotherapy Semin Oncol 1998 Jun25(3 Suppl 7):54–7. [PubMed: 9671332]
  26. Jabs K, Harmon WE Recombinant human erythropoietin therapy in children on dialysis Adv Ren Replace Ther 1996 Jan3>(1):24–36. [PubMed: 8620365]
  27. Jacobs C Normalization of haemoglobin: Why not? Nephrol Dial Transplant 199914(suppl 2):75–9. [PubMed: 10334671]
  28. Jacobs K, Shoemaker C, Rudersdorf R, et al Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313:806–10. [PubMed: 3838366]
  29. Kaufman JS, Reda DJ, Fye CL, et al Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis.Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients N Engl J Med 1998 Aug 27339(9):578–83. [PubMed: 9718376]
  30. Kusunoki M, Kimura K, Nakamura M, et al Effects of hematocrit variations on cerebral blood flow and oxygen transport in ischemic cerebrovascular disease J Cereb Blood Flow Metabol 19811(4):413–7. [PubMed: 7328151]
  31. Levin NW, Lazarus JM, Nissenson AR National Cooperative rHu Erythropoietin Study in patients with chronic renal failure -- an interim report. The National Cooperative rHu Erythropoietin Study Group Am J Kidney Dis 1993 Aug22(2 Suppl 1):3–12. [PubMed: 8352269]
  32. Levin A, Singer J, Thompson CR, et al Prevalent left ventricular hypertrophy in the predialysis population:identifying opportunities for intervention Am J Kidney Dis 1996 Mar27(3):347–54. [PubMed: 8604703]
  33. Levin A, Thompson CR, Ethier J, et al Left ventricular mass index increase in early renal disease:Impact of decline in hemoglobin Am J Kidney Dis 1999 Jul34(1):125–34. [PubMed: 10401026]
  34. Lin F-K, Suggs S, Lin C-H, et al Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985;82:7580–4. [PMC free article: PMC391376] [PubMed: 3865178]
  35. Lowrie EG, Huang WH, Lew NL, et al The relative contribution of measured variables to death risk among hemodialysis patients. In: Friedman EA, ed. Death on hemodialysis. Dordrecht:Kluwer Academic Publishers; 1994. Chapter 13, p. 121-41.
  36. Ludwig H, Fritz E, Leitgeb C, et al Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors Ann Oncol 1993 Feb4(2):161–7. [PubMed: 8448084]
  37. Ma JZ, Ebben J, Xia H, et al Hematocrit level and associated mortality in hemodialysis patients J Am Soc Nephrol 199910(3):610–9. [PubMed: 10073612]
  38. Mason K, McMahon LP Normalization of haemoglobin in haemodialysis patients: A comparative study.14th International Congress of Nephrology; 1997. S305.
  39. Mason K, Skinner SL, Sangkabutra T, et al Effects of erythropoietin on cardiac mass and function, ambulatory blood pressure and blood volumes at comparative levels of haemoglobin. 14th International Congress of Nephrology; 1997. S305.
  40. McEvoy GK, ed Epoetin alfa. In: AHFS drug information 1999. Bethesda: American Society of Health-System Pharmacists; 1999.
  41. McMahon LP, McKenna MJ, Sangkabutra T, et al Physical performance and associated electrolyte changes after haemoglobin normalization:A comparative study in haemodialysis patients Nephrol Dial Transplant 199914(5):1182–87. [PubMed: 10344359]
  42. Moreno F, Lopez-Gomez JM, Sanz-Guajardo D, et al Quality of life in dialysis patients. A Spanish multicentre study Nephrol Dial Transplant 199611(suppl 2):125–9. [PubMed: 8804012]
  43. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients.Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology J Am Soc Nephro 2000 Feb11(2):335–42. [PubMed: 10665941]
  44. Muirhead N, Bargman J, Burgess E, et al Evidence-based recommendations for the clinical use of recombinant human erythropoietin Am J Kidney Dis 1995 Aug26(2 Suppl 1):S1–S24. [PubMed: 7645549]
  45. Healthy People 2010 Objectives: Chronic kidney disease draft chapter (Kidney Subcommittee). Available at: http://www.niddk.nih.gov/federal/kuhdic/kidsub/2010.htm. Last accessed March 2000.
  46. Navarro M, Alonso A, Avilla JM, et al Anemia of chronic renal failure: treatment with erythropoietin Child Nephrol Urol 199111(3):146–51. [PubMed: 1777893]
  47. Procrit® (epoetin alfa) prescribing information. In: Physicians' desk reference. 53rd ed. Montvale: Medical Economics Press; 1999.
  48. Paganini EP, Eschbach JW, Lazarus JM, et al Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients Am J Kidney Dis 1995 Aug26(2):331–40. [PubMed: 7645538]
  49. Perkins SL Normal blood and bone marrow values in humans. In: Lee GR et al., eds. Wintrobe's clinical hematology. 10th ed. Baltimore: Williams and Wilkins; 1999. Appendix A.
  50. Pickett JL, Theberge DC, Brown WS, et al Normalizing hematocrit in dialysis patients improves brain function Am J Kidney Dis 1999 Jun33(6):1122–30. [PubMed: 10352201]
  51. Pincus T, Olsen NJ, Russell IJ, et al Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis Am J Med 1990 Aug89(2):161–8. [PubMed: 2200263]
  52. Riedel E, Hampl H, Nundel M, et al Total correction of renal anemia improves malnutrition and amino acid (AA) metabolism in hemodialysis (HD) patients. J Am Soc Nephrol. 1996;7:–.
  53. Salvarani C, Lasagni D, Casali B, et al Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease J Rheumatol 1991 Aug18(8):1168–71. [PubMed: 1941817]
  54. Scharer K, Klare B, Braun A, et al Treatment of renal anemia by subcutaneous erythropoietin in children with preterminal chronic renal failure Acta Paediatr 1993 Nov82(11):953–8. [PubMed: 8111177]
  55. Scigalla P, Bonzel KE, Bulla M, et al Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. Contrib Nephrol. 1989;76:227–40. [PubMed: 2684524]
  56. Smith DA, Perry PJ The efficacy of ergogenic agents in athletic competition.Part II:Other performance-enhancing agents Ann Pharmacother 1992 May26(5):653–9. [PubMed: 1591427]
  57. Stein RS, Abels RI, Krantz SB Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes Blood 1991 Oct 178(7):1658–63. [PubMed: 1912554]
  58. Stray-Gundersen J, Sams B, Goodkin B, et al Improvement in functional capacity in dialysis patients with regular exercise and correction of anemia. J Am Soc Nephrol. 1997;8:–.
  59. Suzuki M, Tsutsui M, Yokoyama A, et al Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities Artif Organs 1995 Dec19(12):1258–61. [PubMed: 8967885]
  60. Virot JS, Janin G, Guillaumie J, et al Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? Am J Kidney Dis 1996 Sep28(3):400–8. [PubMed: 8804239]
  61. Vreugdenhil G, Swaak AJ The role of erythropoietin in the anaemia of chronic disease in rheumatoid arthritis Clin Rheumatol 1990 Mar9(1):22–7. [PubMed: 2185909]
  62. Wells GA, Coyle D, Lee KM, et al Quality of life effects of normalization of hemoglobin in asymptomatic hemodialysis patients. J Am Soc Nephrol. 1998;9:–.
  63. Wiklund I The Nottingham Health Profile -- a measure of health-related quality of life. Scand J Prim Health Care Suppl. 1990;1:15–8. [PubMed: 2100359]
  64. Wolfe RA, Held PJ, Hulbert-Shearon TE, et al A critical examination of trends in outcomes over the last decade Am J Kidney Dis 1998 Dec32(6 Suppl 4):S9–S15. [PubMed: 9892361]
  65. The European best practice guidelines for the management of anaemia in patients with chronic renal failure Nephrol Dial Transplant 199914(Suppl 5):1–50. [PubMed: 10513295]
  66. Xia H, Ebben J, Ma JZ, et al Hematocrit levels and hospitalization risks in hemodialysis patients J Am Soc Nephrol 199910(6):1309–16. [PubMed: 10361870]
  67. Yalcinkaya F, Tumer N, Cakar N, et al Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis Pediatr Nephrol 1997 Jun11(3):350–2. [PubMed: 9203190]